2. Signaling Pathways
  3. Epigenetics
    PI3K/Akt/mTOR
  4. AMPK
  5. AMPK Isoform
  6. AMPK Inhibitor

AMPK Inhibitor

AMPK Inhibitors (45):

Cat. No. Product Name Effect Purity
  • HY-13418A
    Dorsomorphin
    		Inhibitor 99.91%
    Dorsomorphin (Compound C) is a selective and ATP-competitive AMPK inhibitor (Ki=109 nM in the absence of AMP). Dorsomorphin (BML-275) selectively inhibits BMP type I receptors ALK2, ALK3, and ALK6. Dorsomorphin can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599).
  • HY-13418
    Dorsomorphin dihydrochloride
    		Inhibitor 99.91%
    Dorsomorphin (Compound C) dihydrochloride is a potent, selective and ATP-competitive AMPK inhibitor, with a Ki of 109 nM. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptors ALK2, ALK3, and ALK6. Dorsomorphin dihydrochloride can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599).
  • HY-112083
    BAY-3827
    		Inhibitor 99.72%
    BAY-3827, a chemical probe, is a potent and selective AMPK inhibitor with IC50 values of 1.4 nM at low (10 μM ATP concentration) and 15 nM at high (2 mM ATP concentration). BAY-3827 shows over 500-fold selectivity for most of the 331 kinases. BAY-3827 prevents phosphorylation of acetyl-CoA carboxylase 1 and shows strongest anti-proliferative activity in androgen-dependent prostate cancer cell lines.
  • HY-15142R
    Doxorubicin hydrochloride (Standard)
    		Inhibitor
    Doxorubicin hydrochloride (Standard) is the analytical standard of Doxorubicin hydrochloride. This product is intended for research and analytical applications. Doxorubicin (Hydroxydaunorubicin) hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy.
  • HY-19805
    STO-609
    		Inhibitor 98.20%
    STO-609 is a selective and cell-permeable inhibitor of the Ca2+/calmodulin-dependent protein kinase kinase (CaM-KK), with Ki values of 80 and 15 ng/mL for recombinant CaM-KKα and CaM-KKβ, respectively. STO-609 inhibits AMP-activated protein kinase kinase (AMPKK) activity in HeLa cell lysates with an IC50 ~0.02 g/ml.
  • HY-151361
    AMPK-IN-3
    		Inhibitor 98.51%
    AMPK-IN-3 (compound 67) is a potent and selective AMPK inhibitor with IC50s of 60.7, 107 and 3820 nM for AMPK (α2), AMPK (α1) and KDR, respectively. AMPK-IN-3 inhibits AMPK does not affect cell viability or cause significant cytotoxicity in K562 cells. AMPK-IN-3 can be used in study of cancer.
  • HY-111588
    Xanthoangelol
    		Inhibitor 99.88%
    Xanthoangelol, extracted from Angelica keiskei, suppresses obesity-induced inflammatory responses. Xanthoangelol possesses antibacterial activity. Xanthoangelol inhibits monoamine oxidases. Xanthoangelol induces apoptosis in neuroblastoma and leukemia cells.
  • HY-D1163
    Chromium(III) acetate
    		Inhibitor 99.9%
    Chromium(III) acetate (Chromic acetate) is an AMPK inhibitor that promotes lipogenesis by inhibiting AMPK phosphorylation. Chromium(III) acetate has low toxicity in mammals, with an LD50 of 2365 mg/kg in rats.
  • HY-N0559
    Kirenol
    		Inhibitor 99.82%
    Kirenol is a diterpenoid compound, an orally active apoptosis inducer and signaling pathway regulator, with a Kd value of 5.47 μM against the target CK2. Kirenol promotes the cleavage of Bid into tBid, regulates the protein levels/phosphorylation of Bax, Bcl-2, p53 and p21, and induces caspase-independent apoptosis, S-phase cell cycle arrest, ROS accumulation and cytotoxicity in cancer cells. Kirenol activates the CK2/AKT and AMPK-mTOR-ULK1 pathways, inhibits the signaling of NF-κB, TGF-β/Smads and NLRP3 inflammasome, and regulates the GSK3β, BMP and Wnt/β-catenin pathways. Kirenol induces autophagy, mitophagy and osteoblast differentiation, promotes mitochondrial fusion, and exerts antioxidant, anti-inflammatory, antifibrotic, renoprotective, cardioprotective, neuroprotective and analgesic effects. Kirenol is applicable to research related to chronic myeloid leukemia, ischemic stroke, diabetic nephropathy, heart failure, acute lung injury and osteoporosis.
  • HY-101934
    MARK-IN-2
    		Inhibitor 99.75%
    MARK-IN-2 is a potent microtubule affinity regulating kinase (MARK) inhibitor with an IC50 of 5 nM.
  • HY-112266
    MARK-IN-4
    		Inhibitor 99.63%
    MARK-IN-4 (Compound 18) is a MARK inhibitor with an IC50 of 1 nM. MARK-IN-4 is applicable to Alzheimer's disease research.
  • HY-101933
    MARK-IN-1
    		Inhibitor 99.96%
    MARK-IN-1 is a potent microtubule affinity regulating kinase (MARK) inhibitor with an IC50 of <0.25 nM.
  • HY-N5142
    α-Terpineol
    		Inhibitor 99.74%
    α-Terpineol (with oral activity) can be found in Eucalyptus globulus Labill. α-Terpineol exhibits strong antimicrobial activity against periodontopathic and cariogenic bacteria.α-Terpineol possesses antifungal activity against T. mentagrophytes, and the activity might lead to irreversible cellular disruption. In addition, α-Terpineol exhibits antineuropathic and anti-inflammatory activities. α-Terpineol can be utilized in research related to diarrhea, neuropathic pain, infections, and inflammation.
  • HY-155943
    AMPK-IN-4
    		Inhibitor
    AMPK-IN-4 (compound 19) is a potent inhibitor of (AMPK(α1) and AMPK(α2) with IC50s of 393 nM and 141 nM, respectively. AMPK-IN-4 plays an important role in cancer research.
  • HY-N7071A
    Maduramicin ammonium
    		Inhibitor 99.89%
    Maduramicin ammonium (Maduramycin ammonium) is isolated from the actinomycete Actinomadura rubra. Maduramicin ammonium (Maduramycin ammonium) is an anticoccidial agent for the the treatment of Eimeria spp., E. adenoeides, E. gallopavonis, and E. dispersa infection. Maduramicin ammonium (Maduramycin ammonium) induces cell apoptosis in chicken myocardial cells via intrinsic and extrinsic pathways.
  • HY-W010380
    Methyl succinate
    		Inhibitor 99.94%
    Methyl succinate is a mitochondrial complex II substrate. Methyl succinate can bypass the inhibition of complex I by Metformin (HY-B0627), restore mitochondrial electron transfer, and reduce AMPK phosphorylation. Methyl succinate is capable of protecting MIN6 β-cells and primary rat β-cells from biguanide-induced toxicity and apoptosis in vitro. Methyl succinate can be used in the research of diseases such as diabetes mellitus.
  • HY-114317
    MARK4 inhibitor 1
    		Inhibitor 98.29%
    MARK4 inhibitor 1 is a potent and selective microtubule affinity-regulating kinase 4 (MARK4) inhibitor, with an IC50 of 1.54 μM. MARK4 inhibitor 1 inhibits cancer cell proliferation, metastasis and induces apoptosis.
  • HY-13418G
    Dorsomorphin dihydrochloride (GMP)
    		Inhibitor
    Dorsomorphin dihydrochloride (GMP) is the GMP level of Dorsomorphin dihydrochloride (HY-13418). GMP guidelines are used to produce Dorsomorphin dihydrochloride (GMP). GMP small molecules works appropriately as an auxiliary reagent for cell research manufacture. Dorsomorphin dihydrochloride (GMP) is a potent, selective and ATP-competitive AMPK inhibitor. Dorsomorphin dihydrochloride (GMP) can be used for the research of induced differentiation of pluripotent stem cells (PSCs).
  • HY-161440
    SIK-IN-1
    		Inhibitor 98.91%
    SIK-IN-1 (Compound 53) is an inhibitor for salt-inducible kinase (SIK), which inhibits SIK1, SIK2 and SIK3 with IC50s of 0.1, 0.4 and 1.5 nM, respectively. SIK-IN-1 inhibits the release of TNFa with IC50 of 0.5 nM, stimulates the LPS (HY-D1056) -induced IL-10 release with EC50 of 4 nM in human macrophages.
  • HY-162708
    KHKI-01128
    		Inhibitor 99.95%
    KHKI-01128 is a NUAK2 inhibitor, with an IC50 of 0.024 μM. KHKI-01128 exhibits potent anticancer activity against SW480 colorectal cancer cells.